Francesco Forconi

Francesco Forconi

Southampton, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 114 publications

Acalabrutinib monotherapy as a first-line treatment for CLL: 3 years follow-up of the real-world EPIC study.

Acalabrutinib monotherapy as a first-line treatment for CLL: 3 years follow-up of the real-world EPIC study.

Journal: Blood advances
Published: February 04, 2026

Acalabrutinib monotherapy as a first-line treatment for CLL: 3-year follow-up of the real-world EPIC study.

Acalabrutinib monotherapy as a first-line treatment for CLL: 3-year follow-up of the real-world EPIC study.

Journal: Blood advances
Published: February 04, 2026

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Journal: Blood
Published: January 05, 2026

Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant.

Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant.

Journal: Blood
Published: January 05, 2026

Integrated multi-omic profiling reveals two distinct splenic marginal zone lymphoma subgroups with prognostic relevance.

Integrated multi-omic profiling reveals two distinct splenic marginal zone lymphoma subgroups with prognostic relevance.

Journal: Blood advances
Published: December 09, 2025

Integrated multiomic profiling reveals 2 distinct splenic marginal zone lymphoma subgroups with prognostic relevance.

Integrated multiomic profiling reveals 2 distinct splenic marginal zone lymphoma subgroups with prognostic relevance.

Journal: Blood advances
Published: December 09, 2025

Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.

Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.

Journal: Blood advances
Published: September 17, 2025

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine
Published: June 16, 2025

DC-SIGN Binding to the Surface Ig Oligomannose-type Glycans Promotes Follicular Lymphoma Cell Adhesion and Survival.

DC-SIGN Binding to the Surface Ig Oligomannose-type Glycans Promotes Follicular Lymphoma Cell Adhesion and Survival.

Journal: Blood
Published: May 21, 2025

DC-SIGN binding to the surface immunoglobulin oligomannose-type glycans promotes follicular lymphoma cell adhesion and survival.

DC-SIGN binding to the surface immunoglobulin oligomannose-type glycans promotes follicular lymphoma cell adhesion and survival.

Journal: Blood
Published: May 21, 2025

CD40L and IL-4 suppress NK cell-mediated antibody-dependent cellular cytotoxicity through the HLA-E:NKG2A axis.

CD40L and IL-4 suppress NK cell-mediated antibody-dependent cellular cytotoxicity through the HLA-E:NKG2A axis.

Journal: Immunotherapy advances
Published: April 25, 2025

The origin, diagnosis, and prognosis of oligomannose-type diffuse large B-cell lymphoma.

The origin, diagnosis, and prognosis of oligomannose-type diffuse large B-cell lymphoma.

Journal: Blood
Published: March 14, 2025
Showing 1-12 of 114

Last Updated: 09/26/2026